An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Advanced or Metastatic MTAP-deleted Solid Tumors

In brief

This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathered may help guide how future studies are designed. The entire study is expected to last about four years. People who join the study may receive treatment for around six months and will be followed for about 12 months after their treatment ends. The study plans to enroll participants over a three-year period.

Key facts

Study ID
NCT06568614
Run by
BeOne Medicines
People needed
29
Starts
2024-10-12
Expected to finish
2026-04-13
Last updated by the study team
2026-05-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.